Compare Charles River Laboratories Intl. Inc (CRL) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs EHang Holdings Ltd - ADR — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while EHang Holdings Ltd - ADR trades at $5.49 (market cap $413.36M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 26.9× EHang Holdings Ltd - ADR's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| CRL | EH | |
|---|---|---|
Market Cap | $11.14B | $413.36M |
Sector | Health | Industrials |
52-Week High | $233.60 | $19.99 |
52-Week Low | $145.57 | $5.41 |
Enterprise Value | $14.00B | $353.02M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EHang Holdings (EH) trades at $5.41, down 3.22% on the day, reflecting ongoing volatility in the advanced air mobility sector. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal persistent losses with a net margin of -77.56% in 2025 despite a gross margin of 61.53%. Recent Q1 2026 earnings beat expectations but highlighted a sharp quarterly revenue drop, underscoring execution challenges amid expansion efforts.
The outlook remains high-risk with mixed analyst sentiment; a $6.97 consensus target suggests modest upside, but deep losses and cash burn necessitate careful monitoring of commercialization progress. Key risks include operational scalability, regulatory hurdles, and intense competition in the emerging eVTOL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
